Biography of Tony Charara: Founder and CEO of Mabel -Entrepreneur
Tony Charara's Journey to Health-Tech Leadership
Tony Charara's career has been driven by a passion for
innovation and solving complex health-related problems. With a background in
finance from the University of Sydney, Tony co-founded Mable, Australia's
leading health-tech platform, in 2013 alongside Peter Scutt. His journey
reflects a blend of entrepreneurial spirit, dedication to healthcare, and the
drive to improve the quality of life for individuals who need support in their
daily lives, particularly in the aged care and disability sectors.
Mable: Connecting Care with Those in Need
Mable was created to address the growing demand for
accessible and personalized care services. The platform directly connects
individuals requiring care and support with qualified workers and health
professionals, empowering consumers to live independently. Under Tony's
leadership as Co-Founder and CEO, Mable has become the go-to health-tech
platform in Australia, processing over $1 billion in healthcare funds and
delivering over 600,000 hours of support each month across the nation’s aged
care and disability sectors.
Expanding into Self-Managed Aged Care with HomeMade
Building on the success of Mable, Tony and Peter launched
HomeMade in 2022. HomeMade provides self-managed aged care solutions,
leveraging technology to allow consumers to manage their Home Care Packages
more effectively. This initiative has been a game-changer for over 3,000
customers, helping them navigate and manage more than $100 million in
healthcare funds. Through HomeMade, Tony and his team continue to push the
boundaries of how technology can be used to improve care and support for
elderly Australians.
Tissue Repair: Pioneering Biotech Innovation
In addition to his work at Mable, Tony co-founded Tissue
Repair Limited in 2014, where he serves as the CEO. Tissue Repair is a
clinical-stage biopharmaceutical company that focuses on developing a novel
class of drugs aimed at accelerating wound healing and tissue repair. Their
lead drug candidate, TR-987, is set to enter phase III trials in 2024, with the
potential to revolutionize the treatment of chronic wounds, an area where few
advancements have been made in the past quarter-century.
Innovative Drug TR-987 to Revolutionize Wound Healing
Tissue Repair's TR-987 is a promising drug that stimulates
the body’s natural tissue repair mechanisms, aiming to speed up wound healing
by 30%. This treatment is currently undergoing FDA approval and is poised to be
the first new drug in 25 years for chronic wounds. If successful, TR-987 will
make a significant impact on healthcare by providing a solution to millions of
people suffering from persistent, hard-to-heal wounds, including those with
diabetes and other chronic conditions.
Biography of Tony Charara: Founder and CEO of Mabel -Entrepreneur#health-tech platform#startup#Mabel story#aged care and disability services#age#net w
TR Pro+: Enhancing Recovery After Medical Procedures
In addition to its work with chronic wounds, Tissue Repair
has also developed TR Pro+, a product designed to accelerate skin healing and
reduce recovery time after aesthetic and medical procedures. TR Pro+ has
recently received TGA (Therapeutic Goods Administration) status, a significant
milestone for the company. This product will not only improve recovery for
patients but also revolutionize post-operative care, making a substantial
difference in the medical aesthetics and healthcare industries.
Social Impact Through Technology
Tony’s work at both Mable and Tissue Repair is deeply rooted
in his commitment to using technology to address some of society’s most
pressing healthcare challenges. By harnessing the power of innovation, Tony has
sought to create meaningful solutions that improve the lives of individuals,
whether by enhancing the accessibility of care services or accelerating the
healing process for patients with chronic wounds. His focus on social impact
has been central to his entrepreneurial journey and continues to guide the
direction of both ventures.
Recognition and Awards for Innovation
Tony’s visionary work has not gone unnoticed. He and Peter
were named among the top 100 innovators by The Australian in 2022, a testament
to their achievements in the health-tech space. Additionally, Mable has been
recognized on several prestigious lists, including Deloitte’s Technology Fast
50 from 2018 to 2022 and the AFR’s Fast 100 in 2021. In 2022, Mable won a Good
Design Award for its "Last Minute" feature, developed during the
COVID-19 pandemic, which enabled immediate support for clients in need during
the rapidly evolving health crisis.
Transforming Healthcare for the Better
Through both Mable and Tissue Repair, Tony has been a
driving force in transforming the healthcare landscape in Australia and beyond.
His commitment to combining technology with healthcare services has led to
innovative solutions that directly benefit consumers. By addressing gaps in
aged care and disability services, as well as pioneering new treatments for
chronic wounds, Tony has positioned himself and his companies as leaders in the
health-tech and biotech industries.
A Vision for the Future of Health-Tech
Looking ahead, Tony remains focused on continuing to drive
innovation within the healthcare sector. Whether it’s expanding Mable’s reach
in the health services market or bringing TR-987 to market, Tony is committed
to improving healthcare outcomes for millions. His dedication to solving
complex healthcare problems with technology has made him a key figure in the
industry, and he is poised to continue shaping the future of health-tech for
years to come.
Timeline of Tony Charara's Story
2013: Co-founded Mable, an innovative health-tech platform
for aged care and disability services.
2014: Co-founded Tissue Repair Limited, focusing on
advancing wound healing treatments.
2022: Launched HomeMade, a self-managed aged care solution.
2024: Tissue Repair's drug TR-987 enters Phase III trials
for chronic wound healing.
2022: Mable and Tony recognized among top 100 innovators by
The Australian.
2022: Mable won a Good Design Award for its "Last
Minute" feature.
